| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 49884-0868-15 | 49884-0868 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Jun 27, 2008 | In Use | |
| 54569-0332-03 | 54569-0332 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 26, 1974 | In Use | |
| 42291-0783-50 | 42291-0783 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 26, 2023 | In Use | |
| 54868-5213-00 | 54868-5213 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 25, 2005 | In Use | |
| 00009-0112-05 | 00009-0112 | Irinotecan hydrochloride | Camptosar | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec 30, 2024 | In Use | |
| 00069-0135-01 | 00069-0135 | Bosutinib monohydrate, Bosutinib | Bosulif | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 4, 2012 | In Use | |
| 00093-8199-28 | 00093-8199 | Sunitinib Malate | Sunitinib Malate | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec 22, 2021 | In Use | |
| 12634-0184-63 | 12634-0184 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 22, 1972 | In Use | |
| 68382-0919-01 | 68382-0919 | methylprednisolone | methylprednisolone | 32.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
| 51407-0701-05 | 51407-0701 | APREPITANT | APREPITANT | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Jun 11, 2025 | In Use | |
| 54868-5934-01 | 54868-5934 | Estrogens, Esterified | Menest | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 5, 2008 | In Use | ||
| 55513-0027-01 | 55513-0027 | Darbepoetin alfa | Aranesp | 150.0 ug/.3mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Feb 18, 2011 | In Use | ||
| 63323-0193-55 | 63323-0193 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Apr 1, 2009 | In Use | |
| 00781-2321-51 | 00781-2321 | Aprepitant | Aprepitant | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Dec 27, 2016 | In Use | |
| 55513-0004-01 | 55513-0004 | Darbepoetin alfa | Aranesp | 60.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
| 63323-0710-59 | 63323-0710 | Leucovorin Calcium | Leucovorin Calcium | 200.0 mg/20mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Sep 18, 2010 | In Use | |
| 54868-3348-01 | 54868-3348 | Medroxyprogesterone Acetate | Depo-Provera | 400.0 mg/mL | Hormonal Therapy | Progestin | Intramuscular | Jan 13, 1995 | In Use | ||
| 72143-0253-30 | 72143-0253 | ISOTRETINOIN | ACCUTANE | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Aug 1, 2022 | In Use | |
| 73555-0500-00 | 73555-0500 | Revumenib | Revuforj | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | KMT2A | Oral | Nov 15, 2024 | In Use | |
| 00338-3993-01 | 00338-3993 | ifosfamide | Ifex | 3.0 g/60mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec 30, 1988 | In Use | |
| 00052-0602-02 | 00052-0602 | BACILLUS CALMETTE-GUERIN | TICE BCG | 50.0 mg/50mL | Immunotherapy | Biological Response Modifier | Live Vaccine | Intravesical | Aug 24, 1990 | In Use | |
| 65862-0709-99 | 65862-0709 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug 28, 2015 | In Use | ||
| 57894-0510-01 | 57894-0510 | AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) | RYBREVANT FASPRO | 1600.0 mg/10mL, 20000.0 mg/10mL | Immunotherapy | Bispecific Antibody | EGFR, MET | Subcutaneous | Dec 17, 2025 | In Use | |
| 16729-0090-10 | 16729-0090 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 28, 2010 | In Use | |
| 61703-0304-36 | 61703-0304 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Feb 28, 1994 | In Use |
Found 12250 results — Export these results
Home